Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer’s disease: A 24-month follow-up study
Abstract
Lower cerebrospinal fluid (CSF) levels of neuronal pentraxin receptor (NPTXR) are associated with Alzheimer's disease (AD), but few studies show longitudinal changes in CSF NPTXR. In the present study, CSF NPTXR was measured at 0, 12, and 24 months using an enzyme-linked immunosorbent assay. The study groups included 28 patients with mild cognitive impairment (MCI) (MCI-MCI), 27 MCI patients who progressed to AD (MCI-AD) during the study, and 28 AD patients (AD-AD). Baseline levels were assessed for 46 control individuals. AD patients had lower baseline CSF NPTXR than controls (p = 0.023). Linear mixed models estimated a 6.7% annualized decrease in CSF NPTXR in the AD-AD group, significantly different from MCI-MCI (p = 0.03) and MCI-AD groups (p = 0.048). CSF NPTXR did not correlate with CSF Aβ42 and weakly correlated with CSF Aβ40, T-tau, P-tau (all R 2 < 0.22, p < 0.06). These trends suggest CSF NPTXR may be a candidate biomarker of AD progression but not sufficiently sensitive to resolve when patients convert from MCI to dementia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NPTXR in CSF was measured by ELISA from RayBiotech, which did not meet the optimal criteria for measurements in CSF when validated by the group.
“NPTXR in CSF was measured by ELISA from RayBiotech (RayBio® Human NPTXR ELISA Kit; RayBiotech, USA), which, albeit being used by other groups [93, 94], did not meet the optimal criteria for measurements in CSF when validated by our group.”
NPTXR does not correlate with core AD biomarkers, except in the control group.
“Another study reported no correlation between NPTXR and core AD biomarkers, except in the control group (Lim et al. 2020).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Lim et al. 2020
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · see citing works
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · see citing works
Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD
Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., Bertram, L., Mullin, K., Tanzi, R. E., Blacker, D., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000171450.97464.49 · Cited by 910 · see citing works
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8657-1 · Cited by 447 · see citing works
NPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316 · see citing works
Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramı́rez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 308 · see citing works
Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E., Vanderstichele, H., Brix, B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1285 · Cited by 294 · see citing works
Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00463-x · Cited by 265 · see citing works
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253 · see citing works
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224 · see citing works
Lleó, A., Núñez-Llaves, R., Alcolea, D., Chiva, C., Balateu-Paños, D., Colom-Cadena, M., Gomez-Giro, G., Muñoz, L., Querol-Vilaseca, M., Pegueroles, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001290 · Cited by 219 · see citing works
Sia, G.-M., Béïque, J.-C., Rumbaugh, G., Cho, R., Worley, P. F., & Huganir, R. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.020 · Cited by 201 · see citing works
Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease
Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. R., & Lee, K. H. (2006) · Annals of Neurology · doi:10.1002/ana.21038 · Cited by 185 · see citing works
Dodds, D. C., Omeis, I. A., Cushman, S. J., Helms, J. A., & Perin, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21488 · Cited by 170 · see citing works
The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer
Doni, A., Stravalaci, M., Inforzato, A., Magrini, E. I., Mantovani, A., Garlanda, C., & Bottazzi, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00712 · Cited by 148 · see citing works
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146 · see citing works
Herukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141 · see citing works
Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works
Lleó, A., Alcolea, D. A., Martínez‐Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simonsen, A. H., Verbeek, M. M., Rosa‐Neto, P., Slot, R. E. R., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.01.015 · Cited by 127 · see citing works
Cho, R. W., Park, J. M., Wolff, S. B. E., Xu, D., Hopf, C., Kim, J.-A., Reddy, R. C., Petralia, R. S., Perin, M. S., Linden, D. J., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.010 · Cited by 125 · see citing works
Findley, C. A., Bartke, A., Hascup, K. N., & Hascup, E. R. (2019) · ASN NEURO · doi:10.1177/1759091419855541 · Cited by 124 · see citing works
Longitudinal changes of CSF biomarkers in memory clinic patients
Bouwman, F. H., van der Flier, W. M., Schoonenboom, N. S. M., van Elk, E. J., Kok, A., Rijmen, F., Blankenstein, M. A., & Scheltens, P. (2007) · Neurology · doi:10.1212/01.wnl.0000271375.37131.04 · Cited by 120 · see citing works
Collins, M. A., An, J., Hood, B. L., Conrads, T. P., & Bowser, R. P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00804 · Cited by 98 · see citing works
Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
Buchhave, P., Blennow, K., Zetterberg, H., Stomrud, E., Londos, E., Andreasen, N., Minthon, L., & Hansson, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006294 · Cited by 93 · see citing works
Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls
Kroksveen, A. C., Guldbrandsen, A., Vedeler, C., Myhr, K. M., Opsahl, J. A., & Berven, F. S. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12029 · Cited by 80 · see citing works
Apolipoprotein E 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
Berge, G., Sando, S. B., Rongve, A., Aarsland, D., & White, L. R. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307228 · Cited by 79 · see citing works
Self-citationMerlo, S., Spampinato, S. F., & Sortino, M. A. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13050 · Cited by 78 · see citing works
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
Hu, Y., Hosseini, A., Kauwe, J. S. K., Gross, J., Cairns, N. J., Goate, A., Fagan, A. M., Townsend, R. R., & Holtzman, D. M. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200600999 · Cited by 75 · see citing works
Llano, D. A., Devanarayan, V., & Simon, A. J. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31826d597a · Cited by 70 · see citing works
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68 · see citing works
Shi, M. Y., Movius, J., Dator, R., Aro, P., Zhao, Y., Pan, C., Lin, X., Bammler, T. K., Stewart, T., Zabetian, C. P., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.040576 · Cited by 68 · see citing works
Novel <scp>CSF</scp> biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65 · see citing works
Llano, D. A., Bundela, S., Mudar, R. A., Devanarayan, V., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182098 · Cited by 51 · see citing works
Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martinez-Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Gkioka, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.15095.1 · Cited by 51 · see citing works
Self-citationFoster, C. M., Kennedy, K. M., Horn, M. M., Hoagey, D. A., & Rodrigue, K. M. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.10.068 · Cited by 50 · see citing works
Dodge, H. H., Zhu, J. Y., Harvey, D. J., Saito, N. H., Silbert, L. C., Kaye, J. A., Koeppe, R. A., Albin, R. L., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.513 · Cited by 43 · see citing works
Stomrud, E., Minthon, L., Zetterberg, H., Blennow, K., & Hansson, O. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.002 · Cited by 43 · see citing works
Cummings, D. M., Benway, T. A., Ho, H., Tedoldi, A., Freitas, M. M. F., Shahab, L., Murray, C. E., Richard-Loendt, A., Brandner, S., Lashley, T., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx046 · Cited by 43 · see citing works
Berge, G., Sando, S. B., Albrektsen, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., & White, L. R. (2016) · BMC Neurology · doi:10.1186/s12883-016-0706-0 · Cited by 28 · see citing works
Self-citationLim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0428 · Cited by 25 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112 · see citing works
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82 · see citing works
Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01042-3 · Cited by 39 · see citing works
Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36 · see citing works
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194575 · Cited by 22 · see citing works
- Authors
- Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P.
- Affiliations
- University of Toronto (CA)
- Norwegian University of Science and Technology (NO)
- Mount Sinai Hospital (CA)
- Corresponding author
- Diamandis, Eleftherios P.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 93
- Pages
- 97.e1-97.e7
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W3015186548
- Cited by
- 39
- References
- 41
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 4 · 2022: 11 · 2021: 4 · 2020: 1
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- cerebrospinal fluid biomarkers, Alzheimer's disease, mild cognitive impairment, disease progression, amyloid-beta, tau protein
- MeSH terms
- Pentraxins, Aged, Alzheimer Disease, C-Reactive Protein, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Nerve Tissue Proteins, Time Factors, Biomarkers, Disease Progression, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
